Navigation Links
Drug Treatment Slows Decline in Lung Function in COPD Patients

Treatment with a commonly used drug slows the decline in lung function in patients with chronic obstructive pulmonary disease (COPD), according to results from the TORCH (TOwards a Revolution in COPD Health) study presented at the American Thoracic Society 2007 International Conference.

The study of 6,112 patients from 42 countries found that those treated with salmeterol/fluticasone propionate (Advair) had a slower rate of lung function decline compared with patients receiving a placebo over three years (39 vs. 55 milliliters per year).

"Until now, no intervention except smoking cessation has been shown to alter the rate of decline in lung function for patients with COPD," says one the study authors, Bartolome R. Celli, M.D., of St. Elizabeths Medical Center in Boston. "This is the first time that pharmacotherapy has been shown to change the rate of decline in lung function."

Patients who received either the long-acting beta2-agonist salmeterol (Serevent) or the inhaled corticosteroid fluticasone propionate (Flovent) alone also had less of a decline in lung function than those receiving the placebo, but the decline was smaller than with the combined salmeterol/fluticasone propionate treatment.

The study also found that patients with a low body mass index (BMI) lose more lung function than those with a higher BMI.

The researchers also looked a geographic variations in lung function decline, and found that COPD patients who lived in East Asia and Eastern Europe lost lung function at a slower rate than those who lived in the United States or Western Europe. The study did not address the possible causes for this geographic difference.

The TORCH study is the largest ever, multicenter long-term COPD study. The study compared salmeterol at a dose of 50 mcg plus fluticasone propionate at a dose of 500 mcg twice daily combined in a single inhaler, with placebo, salmeterol alone, or fluticas one propionate alone for a period of three years.

In February 2007, the New England Journal of Medicine published results from the TORCH study that found that the reduction in death rates for patients taking the combination treatment was not significantly different from those in the placebo group. However, treatment with the combination treatment did result in significantly fewer COPD flareups and improved health-related quality of life and lung function, as compared with placebo.


'"/>




Related medicine news :

1. Advances in Treatment of Cataracts
2. Recommendations for Treatment of Blood Pressue
3. Treatment for Menieres disease
4. Treatment for pre-menstrual syndrome is ineffective
5. Better Treatment for obesity
6. Gene Treatment for Heart Disease
7. More People Seeking Treatment for Depression
8. Focused Treatment For Childhood Cancer
9. Inadequate Drug Treatment For Youth
10. FDA Approves New surgery Treatment for Farsightedness
11. Treatment of antibiotics ineffectual in bronchitis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/11/2016)... ... February 11, 2016 , ... Atlantic Information Services, Inc. ... Model: A Case Study for Plans and Purchasers.” Executives from Intel Corp. and ... Intel on value-based health benefits program Connected Care, will discuss the challenges they ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... of J.R. Garrett Esq. as General Counsel. Garrett will focus on contract negotiations, ... and audits, privacy and security law, and best practices in data breaches for ...
(Date:2/11/2016)... ... February 11, 2016 , ... AccuVein Inc. announces ... Therapy Standards of Practice, to include vascular visualization as a standard practice. AccuVein ... share of the market, facilitates adherence to this standard with its easy to ...
(Date:2/11/2016)... ... February 11, 2016 , ... The annual list showcases the 20 Most Promising ... team dedication and commitment to the SharePoint ecosystem. A panel of experts and ... goal is to recognize and promote technology entrepreneurship. , The survey was made ...
(Date:2/11/2016)... Utah (PRWEB) , ... February 11, 2016 , ... ... microFET medical dynamometers and ergoFET force gauges used in physical therapy, occupational therapy ... Strength Indicator sensor for resistance cord exercise and therapy, introduces its new microFET ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... Feb. 11, 2016  Kindred Biosciences, Inc. (NASDAQ: ... improving the lives of pets, today announced the submission ... New Animal Drug Application (NADA) for Zimeta™ (dipyrone injection, ... (KB0120) of Zimeta for the control of pyrexia (fever) ... --> --> The Chemistry, ...
(Date:2/11/2016)... Potrero Medical, Inc., the developer of the Accuryn™ ... of George M. Rapier, III , MD, to its ... , WellMed is one of the nation,s largest physician owned ... in Texas and Florida ... own internal medicine practice, he has been instrumental to the ...
(Date:2/11/2016)... Feb. 11, 2016  AfterPill.com is reporting that this ... abstinence for all women who are at risk of ... each year and raises the risks of unprotected sex ... --> According to the Guttmacher Institute, there are ... of child-bearing age, who have sex without the intention ...
Breaking Medicine Technology: